Showing results (1-10 of 53) with videos related to
Sort By:
Pageof 6
Future Microbiology|October 31, 2015
Overcoming drug resistance for tuberculosisGiovanna Poce, Mariangela BiavaExpert Opinion on Therapeutic Patents|November 14, 2015
COX inhibitors: a patent review (2011 - 2014)Sara Consalvi, Mariangela Biava, Giovanna PoceMini Reviews in Medicinal Chemistry|January 19, 2016
MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same TargetGiovanna Poce, Sara Consalvi, Mariangela BiavaExpert Opinion on Therapeutic Patents|May 29, 2009
C-9 Alkenylidine bridged macrolides: WO2008061189. Enanta Pharmaceuticals, IncGiovanna Poce, Giulio Cesare Porretta, Mariangela BiavaEuropean Journal of Medicinal Chemistry|September 1, 2014
SAR analysis of new anti-TB drugs currently in pre-clinical and clinical developmentGiovanna Poce, Martina Cocozza, Sara Consalvi, et al.Bioorganic & Medicinal Chemistry Letters|October 20, 2019
Mycobacterial tryptophan biosynthesis: A promising target for tuberculosis drug development?Sara Consalvi, Cristina Scarpecci, Mariangela Biava, et al.Expert Opinion on Therapeutic Patents|August 7, 2019
Novel therapies for glaucoma: a patent review (2013-2019)Paolo Guglielmi, Simone Carradori, Cristina Campestre, et al.Chemsuschem|September 12, 2018
Stimuli-Responsive Tannin-FeElisavet D Bartzoka, Heiko Lange, Giovanna Poce, et al.Proceedings of the National Academy of Sciences of the United States of America|July 13, 2017
MmpL3 is the flippase for mycolic acids in mycobacteriaZhujun Xu, Vladimir A Meshcheryakov, Giovanna Poce, et al.Pharmaceuticals (Basel, Switzerland)|September 4, 2020
SAR Analysis of Small Molecules Interfering with Energy-Metabolism in Mycobacterium tuberculosisFederico Appetecchia, Sara Consalvi, Cristina Scarpecci, et al.Pageof 6